<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127772</url>
  </required_header>
  <id_info>
    <org_study_id>HEC93077-HUA-101</org_study_id>
    <nct_id>NCT05127772</nct_id>
  </id_info>
  <brief_title>A Phase 1 Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple Dosing.</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Single and Multiple Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Randomized, Open-label，Crossover, Food Effect Study of HEC93077 in Healthy Chinese Subjects and Hyperuricemia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1 clinical trial of HEC93077,to evaluate the safety ,PK,PD and food effect in Chinese&#xD;
      healthy subjects and HUA patients after single or multiple dosing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2021</start_date>
  <completion_date type="Anticipated">November 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Number of Adverse Events (AEs)</measure>
    <time_frame>up to 25 days</time_frame>
    <description>To investigate the safety and tolerability by assement of AEs following administration of oral solution in SAD and MAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters - AUC0-∞</measure>
    <time_frame>up to 18 days</time_frame>
    <description>Area Under the Curve(AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters - Cmax</measure>
    <time_frame>up to 18 days</time_frame>
    <description>Geometric Mean of Maximum Observed Plasma Concentration of HEC93077</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters -tmax</measure>
    <time_frame>up to 18 days</time_frame>
    <description>maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters -t½</measure>
    <time_frame>up to 18 days</time_frame>
    <description>apparent terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters -Vz/F</measure>
    <time_frame>up to 18 days</time_frame>
    <description>apparent volume of distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD parameters</measure>
    <time_frame>up to 18 days</time_frame>
    <description>Percentage of serum uric acid changed from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters - Ae0-t(urine)</measure>
    <time_frame>up to 18 days</time_frame>
    <description>The amount of drug excreted in the urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters - Ae0-t(feces)</measure>
    <time_frame>up to 18 days</time_frame>
    <description>The amount of drug excreted in the feces</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters-The cumulative rate of excretion</measure>
    <time_frame>up to 18 days</time_frame>
    <description>The cumulative rate of durg excreted through urine/feces</description>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>single dose of HEC93077（pilot trial arm）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive single dose of HEC93077</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose of HEC93077（Cohort 1）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive sinele dose of HEC93077 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose of HEC93077（Cohort 2）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive sinele dose of HEC93077 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose of HEC93077（Cohort 3,Fed/Fasting）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following an overnight fast of at least 10 hours, a single dose of HEC93077 or placebo will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose of HEC93077（Cohort 4）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive sinele dose of HEC93077 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose of HEC93077（Cohort 5）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive sinele dose of HEC93077 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose of HEC93077（Cohort 6）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive sinele dose of HEC93077 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose of HEC93077（Cohort 7）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive sinele dose of HEC93077 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple doses of HEC93077（ Cohort 8）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive multiple doses of HEC93077 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple doses of HEC93077（ Cohort 9, Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive multiple doses of HEC93077 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple doses of HEC93077（ Cohort 9, Gruop 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperuricemia subjects receive multiple doses of HEC93077 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple doses of HEC93077（ Cohort 10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive multiple doses of HEC93077 or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC93077</intervention_name>
    <description>Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days</description>
    <arm_group_label>multiple doses of HEC93077（ Cohort 10)</arm_group_label>
    <arm_group_label>multiple doses of HEC93077（ Cohort 8）</arm_group_label>
    <arm_group_label>multiple doses of HEC93077（ Cohort 9, Group 1)</arm_group_label>
    <arm_group_label>multiple doses of HEC93077（ Cohort 9, Gruop 2)</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 1）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 2）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 3,Fed/Fasting）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 4）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 5）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 6）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 7）</arm_group_label>
    <arm_group_label>single dose of HEC93077（pilot trial arm）</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days</description>
    <arm_group_label>multiple doses of HEC93077（ Cohort 10)</arm_group_label>
    <arm_group_label>multiple doses of HEC93077（ Cohort 8）</arm_group_label>
    <arm_group_label>multiple doses of HEC93077（ Cohort 9, Group 1)</arm_group_label>
    <arm_group_label>multiple doses of HEC93077（ Cohort 9, Gruop 2)</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 1）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 2）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 3,Fed/Fasting）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 4）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 5）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 6）</arm_group_label>
    <arm_group_label>single dose of HEC93077（Cohort 7）</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy Subjects：&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are willing and are able to provide a written informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          2. Subjects aged between 18 and 45 (both inclusive) years old.&#xD;
&#xD;
          3. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body&#xD;
             mass index ≥19 and ≤28 kg/m2 at screening.&#xD;
&#xD;
          4. Subjects, who are healthy, as having no clinically significant abnormalities in vital&#xD;
             signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
          5. Without Plan for pregnancy or pregnant within 3 months after enrollment throughout the&#xD;
             trial.&#xD;
&#xD;
          6. Serum uric acid≥240 and&lt;420 at screening.&#xD;
&#xD;
          7. GFR≥90 mL/min/1.73 m2 at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. At screening subjects have the following diseases of clinical significance, including&#xD;
             but not limited to cardiovascular system diseases, digestive system diseases,&#xD;
             respiratory system diseases, urinary system diseases, endocrine and metabolic system&#xD;
             diseases, blood system diseases, central nervous system and/or mental system diseases,&#xD;
             immune system diseases, tumors, etc.&#xD;
&#xD;
          2. A history of gastrointestinal, liver, or kidney disease or surgery prior to screening&#xD;
             that could potentially affect the absorption, distribution, metabolism, and excretion&#xD;
             of the test drug (except for uncomplicated appendectomy and hernia repair);&#xD;
&#xD;
          3. History of urolithiasis or ultrasound screening showed urolithiasis, renal/ureteral&#xD;
             malformation, unirenal or renal atrophy, polycystic kidney and other urological&#xD;
             diseases&#xD;
&#xD;
          4. History of gout and/or hyperuricemia&#xD;
&#xD;
          5. Acute illness or concomitant use from signing the ICF to initial dosing.&#xD;
&#xD;
          6. Known allergic reactions or hypersensitivity to any excipient of the drug&#xD;
             formulation(s)， anaphylaxis physique.(Allergic to more than 3 foods and/or&#xD;
             medications)&#xD;
&#xD;
          7. History of alcoholism or drink regularly within 3 months prior to the study(defined as&#xD;
             Alcohol consumption of &gt; 21 units/week), or positive results from alcohol breath test&#xD;
             at screening.&#xD;
&#xD;
          8. History of drug abuse, or use of drugs within 2 years prior to the study,or positive&#xD;
             results from urine drug screen test at screening.&#xD;
&#xD;
          9. Regular smoking of more than 10 cigarettes per day within 3 months before screening&#xD;
             period, or inability to refrain from smoking during the course of the study after&#xD;
             signing ICF.&#xD;
&#xD;
         10. Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies,&#xD;
             hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP&#xD;
             antibodies at screening.&#xD;
&#xD;
         11. Use of any prescription or non-prescription medications、vitamin and traditional&#xD;
             Chinese medicine within 2 weeks prior to initial dosing,or use of any mediciations&#xD;
             which affect UA synthesize,metabolize and excrete within 4 weeks prior to initial&#xD;
             dosing.&#xD;
&#xD;
         12. Use of any medications known to strongly inhibit and/or induce cytochrome P enzyme&#xD;
             drug metabolism within 4 weeks prior to initial dosing.&#xD;
&#xD;
         13. Have taken any food or drink that affects CYP3A4 and/or CYP1A2 metabolic enzymes&#xD;
             within 2 days prior to initial dosing,such as grapefruit or grapefruit drink.&#xD;
&#xD;
         14. Have taken chocolate, any food or drink containing caffeine or rich in xanthine within&#xD;
             72 hours prior to initial dosing.&#xD;
&#xD;
         15. Have taken any alcoholic product within 48 hours prior to initial dosing.&#xD;
&#xD;
         16. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.&#xD;
&#xD;
         17. Subjects who plan to receive or have had organ transplants.&#xD;
&#xD;
         18. Females who are lactating/breastfeeding, or positive result from pregnancy test for&#xD;
             women of child-bearing potential.&#xD;
&#xD;
         19. Subjects who participated in another clinical trial within 3 months prior to initial&#xD;
             dosing.&#xD;
&#xD;
         20. Subjects who canot tolerate fat food.(only suitable to FE trial)&#xD;
&#xD;
         21. Subjects who maynot complete for other reasons.&#xD;
&#xD;
         22. Any other condition with in the opinion of the investigator would render the patient&#xD;
             unsuitable for inclusion in the study.&#xD;
&#xD;
        Hyperuricemia Patients：&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are willing and are able to provide a written informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          2. Patients aged between 18 and 60 (both inclusive) years old.&#xD;
&#xD;
          3. Patients has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body mass&#xD;
             index ≥19 and ≤30 kg/m2 at screening.&#xD;
&#xD;
          4. During screening period, serum uric acid was ≥480 µmol/L twice on different&#xD;
             days.Patients are considered to need to lower UA with a long term therapy;&#xD;
&#xD;
          5. Without Plann for pregnancy or pregnant within 3 months after enrollment throughout&#xD;
             the trial.&#xD;
&#xD;
          6. GFR≥90 mL/min/1.73 m2 at screening.&#xD;
&#xD;
        Exclusion Criteria:（mainly different with healthy subjects）&#xD;
&#xD;
          1. Patients with myocardial infarction, angina pectoris, percutaneous coronary&#xD;
             angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral&#xD;
             hemorrhage, subarachnoid hemorrhage or transient ischemic attack within 6 months prior&#xD;
             to screening.&#xD;
&#xD;
          2. History of acute gout attack prior to initial dosing;&#xD;
&#xD;
          3. Acute illness or use of a contraindicated drug under the protocol from signing the ICF&#xD;
             to initial dosing.&#xD;
&#xD;
          4. At screening,AST or ALT or TBIL &gt;1.2 × ULN, or sCr &gt;ULN，or HbA1c&gt;8%.&#xD;
&#xD;
        4.Investigator judged the following conditons unsuitable for inclusion:Medical history,&#xD;
        physical examination, electrocardiogram, chest X-ray, ultrasonic examination of digestive&#xD;
        system , ultrasonic examination of urinary system and laboratory examination have abnormal&#xD;
        and clinical significance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jie Hou, doctor</last_name>
    <phone>0533-7698222</phone>
    <email>jie.hou@gohealtharo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Universicity Care of Luzhong Hospital</name>
      <address>
        <city>Zibo</city>
        <state>Shandong</state>
        <zip>255400</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie Hou, doctor</last_name>
      <phone>0533-7698222</phone>
      <email>jie.hou@gohealtharo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

